MAP-quest: Could we produce constitutively active variants of MAP kinases?

被引：15

作者：

Askari, Nadav ^{[1
]}

Diskin, Ron ^{[1
]}

Avitzour, Michal ^{[1
]}

Yaakov, Gilad ^{[1
]}

Livnah, Oded ^{[1
]}

Engelberg, David ^{[1
]}

机构：

[1] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2006年 / 252卷 / 1-2期

关键词：

ERK; p38; JNK; HOG1; MAP kinase; gain-of-function mutations;

D O I：

10.1016/j.mce.2006.03.015

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Constitutively active mutants that acquired intrinsic activity and escaped regulation, serve as powerful tools for revealing the biochemical, biological and pathological functions of proteins. Such mutants are not available for mitogen-activated protein kinases (MAPKs). It is not known how to mimic the unusual mode of MAPK activation and to enforce, by mutations, their active conformation. In this review we describe the strategies employed in attempts to overcome this obstacle. We focus on a recent breakthrough with the p38 family that suggests that active variants of all MAPKs will soon be available. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

收藏

页码：231 / 240

页数：10

相关论文

共 105 条

[41] C-HA-RAS-1 ALLELES IN BLADDER-CANCER, WILMS TUMOR AND MALIGNANT-MELANOMA [J].

HAYWARD, NK ;

KEEGAN, R ;

NANCARROW, DJ ;

LITTLE, MH ;

SMITH, PJ ;

GARDINER, RA ;

SEYMOUR, GJ ;

KIDSON, C ;

LAVIN, MF .

HUMAN GENETICS, 1988, 78 (02) :115-120

[42] Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease [J].

Hommes, D ;

Van Den Blink, B ;

Plasse, T ;

Bartelsman, J ;

Xu, CP ;

MacPherson, B ;

Tytgat, G ;

Peppelenbosch, M ;

Van Deventer, S .

GASTROENTEROLOGY, 2002, 122 (01) :7-14

[43] Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b [J].

Huang, S ;

Jiang, Y ;

Li, ZJ ;

Nishida, E ;

Mathias, P ;

Lin, SC ;

Ulevitch, RJ ;

Nemerow, GR ;

Han, JH .

IMMUNITY, 1997, 6 (06) :739-749

[44] Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma [J].

Ikeda, H ;

Ohta, N ;

Furukawa, K ;

Miyazaki, H ;

Wang, LJ ;

Furukawa, K ;

Kuribayashi, K ;

Old, LJ ;

Shiku, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (12) :6375-6379

[45] Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development [J].

Ip, YT ;

Davis, RJ .

CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (02) :205-219

[46]

Jackson Paul F., 2002, Current Topics in Medicinal Chemistry, V2, P1011, DOI 10.2174/1568026023393372

[47] Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation [J].

Khokhlatchev, AV ;

Canagarajah, B ;

Wilsbacher, J ;

Robinson, M ;

Atkinson, M ;

Goldsmith, E ;

Cobb, MH .

CELL, 1998, 93 (04) :605-615

[48]

Kolibaba K, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217

[49] Targeting the JNK Signaling Pathway for Stroke and Parkinson's Diseases Therapy [J].

Kuan, Chia-Yi ;

Burke, Robert E. .

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (01) :63-67

[50] p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases [J].

Kumar, S ;

Boehm, J ;

Lee, JC .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :717-726

← 1 2 3 4 5 6 7 8 9 10 →